메뉴 건너뛰기




Volumn 101, Issue 23, 2004, Pages 2003-2006

Memantine can relieve certain symptoms in Parkinson's disease;Memantin kan lindra vissa symtom vid Parkinsons sjukdom: Förbättring i två av tre beskrivna patientfall med dyskinesi och kognitiv svikt

Author keywords

[No Author keywords available]

Indexed keywords

LEVODOPA; MEMANTINE; ANTIPARKINSON AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

EID: 3042567248     PISSN: 00237205     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article
Times cited : (18)

References (21)
  • 2
    • 0027500750 scopus 로고
    • Treatment of Parkinson's disease
    • Calne DB. Treatment of Parkinson's disease. N Engl J Med 1993; 329:1021-27.
    • (1993) N Engl J Med , vol.329 , pp. 1021-1027
    • Calne, D.B.1
  • 3
    • 0001905621 scopus 로고    scopus 로고
    • Pathophysiology and clinical assessment of motor symptoms in Parkinson's disease
    • Koller W, editor. New York: Marcel Dekker Inc
    • Jankovic J. Pathophysiology and clinical assessment of motor symptoms in Parkinson's disease. In: Koller W, editor. Handbook of Parkinson's disease. New York: Marcel Dekker Inc; 2003. p.99-126.
    • (2003) Handbook of Parkinson's Disease , pp. 99-126
    • Jankovic, J.1
  • 6
    • 0037769604 scopus 로고    scopus 로고
    • Cognitive and behavioral disturbances in Parkinson's disease
    • Girotti F, Soliveri P. Cognitive and behavioral disturbances in Parkinson's disease. Neurol Sci 2003;24 Suppl 1:S30-1.
    • (2003) Neurol Sci , vol.24 , Issue.1 SUPPL.
    • Girotti, F.1    Soliveri, P.2
  • 7
    • 0034642340 scopus 로고    scopus 로고
    • Pulsatile stimulation of dopamine receptors and levodopa-induced motor complications in Parkinson's disease: Implications for the early use of COMT inhibitors
    • Olanow CW, Obeso JA. Pulsatile stimulation of dopamine receptors and levodopa-induced motor complications in Parkinson's disease: implications for the early use of COMT inhibitors. Neurology 2000; 55 Suppl 4:S72-77.
    • (2000) Neurology , vol.55 , Issue.4 SUPPL.
    • Olanow, C.W.1    Obeso, J.A.2
  • 8
    • 0034684139 scopus 로고    scopus 로고
    • Pramipexole vs levodopa as initial treatment for Parkinson's disease: A randomized controlled trial
    • Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson's disease: A randomized controlled trial. JAMA 2000;284:1931-8.
    • (2000) JAMA , vol.284 , pp. 1931-1938
  • 9
    • 18744437329 scopus 로고    scopus 로고
    • The role of glutamatergic transmission in the pathogenesis of levodopa-induced dyskinesias. Potential therapeutic approach
    • Merims D, Ziv I, Sherki Y, Djaldetti R, Melamed E. The role of glutamatergic transmission in the pathogenesis of levodopa-induced dyskinesias. Potential therapeutic approach. Neurol Neurochir Pol 2001;35 Suppl 3:65-8.
    • (2001) Neurol Neurochir Pol , vol.35 , Issue.3 SUPPL. , pp. 65-68
    • Merims, D.1    Ziv, I.2    Sherki, Y.3    Djaldetti, R.4    Melamed, E.5
  • 10
    • 0033971510 scopus 로고    scopus 로고
    • Pathophysiology of motor response complications in Parkinson's disease: Hypotheses on the why, where, and what
    • Metman LV, Konitsiotis S, Chase TN. Pathophysiology of motor response complications in Parkinson's disease: hypotheses on the why, where, and what. Mov Disord 2000;15:3-8.
    • (2000) Mov Disord , vol.15 , pp. 3-8
    • Metman, L.V.1    Konitsiotis, S.2    Chase, T.N.3
  • 11
    • 0034932441 scopus 로고    scopus 로고
    • Amantadine for dyskinesia in patients affected by severe Parkinson's disease
    • Paci C, Thomas A, Onofrj M. Amantadine for dyskinesia in patients affected by severe Parkinson's disease. Neurol Sci 2001;22:75-6.
    • (2001) Neurol Sci , vol.22 , pp. 75-76
    • Paci, C.1    Thomas, A.2    Onofrj, M.3
  • 13
    • 0032983786 scopus 로고    scopus 로고
    • Memantine in severe dementia: Results of the 9M-Best Study. Benefit and efficacy in severely demented patients during treatment with memantine
    • Winblad B, Poritis N. Memantine in severe dementia: results of the 9M-Best Study. Benefit and efficacy in severely demented patients during treatment with memantine. Int J Geriatr Psychiatry 1999; 14:135-46.
    • (1999) Int J Geriatr Psychiatry , vol.14 , pp. 135-146
    • Winblad, B.1    Poritis, N.2
  • 15
    • 0026701318 scopus 로고
    • Efficacy of memantine, an NMDA receptor antagonist, in the treatment of Parkinson's disease
    • Rabey JM, Nissipeanu P, Korczyn AD. Efficacy of memantine, an NMDA receptor antagonist, in the treatment of Parkinson's disease. J Neural Transm 1992;4:277-82.
    • (1992) J Neural Transm , vol.4 , pp. 277-282
    • Rabey, J.M.1    Nissipeanu, P.2    Korczyn, A.D.3
  • 16
    • 0032730121 scopus 로고    scopus 로고
    • Effect of memantine (NMDA antagonist) on Parkinson's disease: A double-blind crossover randomized study
    • Merello M, Nouzeilles MI, Cammarota A, Leiguarda R. Effect of memantine (NMDA antagonist) on Parkinson's disease: A double-blind crossover randomized study. Clin Neuropharmacol 1999; 22(3):273-6.
    • (1999) Clin Neuropharmacol , vol.22 , Issue.3 , pp. 273-276
    • Merello, M.1    Nouzeilles, M.I.2    Cammarota, A.3    Leiguarda, R.4
  • 17
    • 0035353725 scopus 로고    scopus 로고
    • Frequency of levodopa-related dyskinesia and motor fluctuations as estimated from the literature
    • Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesia and motor fluctuations as estimated from the literature. Mov Disord 2001;16:448-58.
    • (2001) Mov Disord , vol.16 , pp. 448-458
    • Ahlskog, J.E.1    Muenter, M.D.2
  • 18
    • 0032554497 scopus 로고    scopus 로고
    • Adverse reactions to levodopa: Drug toxicity or progression of the disease?
    • Agid Y, Chase T, Marsden D. Adverse reactions to levodopa: drug toxicity or progression of the disease? Lancet 1998;351:851-2.
    • (1998) Lancet , vol.351 , pp. 851-852
    • Agid, Y.1    Chase, T.2    Marsden, D.3
  • 19
    • 0031976069 scopus 로고    scopus 로고
    • The significance of continuous dopaminergic stimulation in the treatment of Parkinson's disease
    • Chase TN. The significance of continuous dopaminergic stimulation in the treatment of Parkinson's disease. Drugs 1998;55 Suppl 1:1-9.
    • (1998) Drugs , vol.55 , Issue.1 SUPPL. , pp. 1-9
    • Chase, T.N.1
  • 21
    • 17344374331 scopus 로고    scopus 로고
    • Clinical experience with cabergoline in patients with advanced Parkinson's disease treated with levodopa
    • Marsden CD. Clinical experience with cabergoline in patients with advanced Parkinson's disease treated with levodopa. Drugs 1998;55 Suppl 1:17-22.
    • (1998) Drugs , vol.55 , Issue.1 SUPPL. , pp. 17-22
    • Marsden, C.D.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.